Home › Funds › Catalys Pacific, LLC › PHAT

Catalys Pacific, LLC position in PHAT

Phathom Pharmaceuticals, Inc. · Health Care

Catalys Pacific, LLC reported holding 1,882,039 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$13.7M, representing 6.55% of its reported portfolio and ranking #2 among its reported holdings. Catalys Pacific, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)1.88M sh
Reported value held$13.74M
Portfolio Weight6.55%
First reportedQ4 2023
Last changeAdd
Updated2026-10-30

Last updated: 2026-10-30 · Source: SEC EDGAR Form 13F-HR

How Catalys Pacific, LLC's PHAT position evolved

Catalys Pacific, LLC first disclosed a stake in PHAT in Q4 2023 at 721,962 shares (US$6.6M). The position peaked in Q4 2025 at 1,429,014 shares, worth US$23.7M. Across 12 filings, Catalys Pacific, LLC increased the stake 5 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,882,039 shares valued at US$13.7M — an increase of 388,185 shares quarter over quarter.. Notable position changes include a 55% increase in Q3 2024 (shares fell 55% over the following quarter), a 26% increase in Q3 2026 (shares fell 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 721.96K $6.59M New
Q1 2024 721.96K $7.67M Hold
Q2 2024 721.96K $7.44M Hold
Q3 2024 1.12M $20.30M Add
Q4 2024 1.17M $9.48M Add
Q1 2025 1.17M $7.32M Hold
Q2 2025 1.17M $11.19M Hold
Q3 2025 1.17M $13.74M Hold
Q4 2025 1.43M $23.71M Add
Q1 2026 1.49M $16.60M Add
Q2 2026 1.49M $16.21M Hold
Q3 2026 1.88M $13.74M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHAT and 13F data

PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 30 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHAT

All PHAT fund holders →

FAQ

How long has Catalys Pacific, LLC held PHAT?

Catalys Pacific, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Catalys Pacific, LLC's current position in PHAT?

As of Q3 2026, Catalys Pacific, LLC holds 1.88M shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $13.74M, representing 6.55% of its reported portfolio and ranking #2.

Has Catalys Pacific, LLC been buying or selling PHAT?

In the latest 13F filing (Q3 2026), Catalys Pacific, LLC increased its position in PHAT. The position peaked in Q4 2025 at 1.43M shares.

Which other funds hold PHAT?

Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.